Suven Life Sciences Q4 FY19 results (Jan–Mar 2019) and concall

Suven Life Sciences reported strong sequential growth in Q4 FY19 with revenue up 90% and PAT up 170%, though full-year FY19 saw a 6% top-line growth and a 5% bottom-line decline due to product mix and raw material costs. The company provided optimistic guidance for FY20, expecting 10-15% growth in Core CRAMS and a 20% increase in standalone bottom-line. A significant highlight was the completion of the SUVN-502 Phase 2 trial, with results anticipated by July, and a strategic USD 35 million investment in Shore Pharma to bolster its ANDA pipeline and market presence.